Inhibition of farnesyltransferase (FT) activity has been associated with in vitro and in vivo anti-leukemia activity. We report the results of a phase 1 dose-escalation study of tipifarnib, an oral FT inhibitor, in patients with relapsed, refractory or newly diagnosed (if over age 70) acute myelogenous leukemia (AML), on a week-on, week-off schedule. Forty-four patients were enrolled, two patients were newly diagnosed, and the rest were relapsed or refractory to previous treatment, with a median age of 61 (range 33-79). The maximum tolerated dose was determined to be 1200 mg given orally twice daily (b.i.d.) on this schedule. Cycle 1 dose-limiting toxicities were hepatic and renal. There were three complete remissions seen, two at the 1200 mg b.i. 
Introduction
Inhibition of farnesyltransferase (FT) activity has been associated with activity against leukemias in vitro and in vivo. Farnesylation is essential to proper functioning of ras, 1 a key protein in various signaling pathways. After farnesylation, ras localizes at the plasma membrane, where it acts as a molecular switch in response to various tyrosine kinase and other cell surface receptors. Initially, ras was identified as a potential target in myeloid malignancies owing to the frequency of N-ras mutations in acute myelogenous leukemia (AML) and myelodysplasia (MDS). However, clinical trials thus far have shown activity for FT inhibitors even in the absence of RAS mutation, 2 suggesting that interference with unmutated ras is itself an effective antineoplastic approach, and/or that other farnesylated proteins, such as rhoB or the lamins, may also be inhibited. 3 As there are over 1000 farnesylated proteins, it remains unclear which are targeted by FT inhibitors, and which are clinically relevant. Inhibition of farnesylation on specific proteins may differ depending on the dosing and schedule of the FT inhibitor.
Tipifarnib (R115777, Zarnestra) is a methylquinolone analog that competes with the CAAX motif for farnesylation. The initial phase1 trial, R115777-USA-1, conducted at the National Cancer Institute, used a 5-day, every 12 h, dosing regimen with an intra-patient and inter-patient dose-escalation scheme. 4 Protocol-defined maximum tolerated dose (MTD) was not achieved at the highest dose level (1300 mg twice daily (b.i.d.) for 5 days).
Tipifarnib was studied in myeloid and lymphoid leukemias by Karp et al.,
2 with a dose escalation built upon a 21-day continuous dosing schedule. A 29% overall response rate was noted in 34 patients, including a complete remission (CR) at the lowest dose level (100 mg b.i.d.). In a follow-up phase 2 study, with dosing at 600 mg b.i.d. using the same 21-day schedule in older patients with previously untreated AML or MDS, CR was observed in 14% of patients, with an additional 10% showing partial response. 5 A study at MD Anderson, for patients with MDS, also using the 21-day b.i.d. dosing schedule, demonstrated a 30% response rate in 20 patients. 6 Their MTD was 400 mg b.i.d.; above that dose there were several dose-limiting toxicities (DLTs), including headache, fatigue, confusion and vision changes.
It is conceivable that altering the dosing schedule so that tipifarnib is given in a week-on, week-off schedule may allow tolerance of administration at higher dose. In a California Cancer Consortium solid tumor phase 1 study of week-on, week-off dosing, a DLT of grade 3 fatigue occurred at the 900 mg b.i.d. dose level; no other significant grade 3 toxicities were noted. 7 In hematological malignancies, a trial of tipifarnib given on a week-on, week-off schedule in patients with highgrade myelodysplastic syndrome showed reasonable tolerability and responses at different dose levels. Importantly, correlative studies performed during this trial and others have demonstrated FT inhibition for 7 days after administration of tipifarnib, [6] [7] [8] suggesting that this alternate-week dosing schedule is mechanistically appropriate, and that dose escalation on this schedule might enhance the activity of tipifarnib in relapsed, refractory AML.
Thus, we propose a study of this dose-escalation regimen in acute myeloid malignancies. Pharmacokinetic studies were done to determine the effect of dose on blood levels. Should this regimen be equally effective as conventional-dose tipifarnib monotherapy, but with better tolerability and advantageous pKs, it could serve as a platform for combination with other agents and chemotherapies.
Patients and methods

Patient selection
Eligible patients were aged X18 with acute myeloid leukemia (AML) including relapsed or refractory disease after one to three previous induction regimens (not counting consolidation therapies while in CR, such as autologous transplant), patients aged p70 with newly diagnosed disease having poor risk features (unfavorable cytogenetics or findings suggestive of previous MDS) not fit for standard induction therapy and patients aged 70-75 with newly diagnosed AML not fit for standard therapy (without history of previous MDS). Patients with acute promyelocytic leukemia of the M3 subtype were excluded. Bone marrow and peripheral blood studies were required for confirmation of diagnosis. Patients who had been treated with previous autologous transplant were eligible and patients post allogeneic transplant were allowed in the expansion cohort as long as there was no active graft-versus-host disease or infectious disease related to transplant. A minimum of 4 weeks must have elapsed since completion of previous chemotherapy in order to be eligible. Standard end-organ function criteria were applied, such as serum bilirubin p2.0 mg/dl, aspartate aminotransferase and alanine aminotransferase p2.5 times the institutional upper limits of normal and excluding patients with a pretreatment calculated creatinine clearance (absolute value) of o60 ml/min or serum creatinine of o1.5 Â upper limit of normal. There were no minimum hematological parameter requirements before enrollment, as patients with AML and MDS are understood to have low aboslute neutrophil count and platelet counts when the disease is active. However, patients with white blood cell count 430 000 received hydroxyurea to reduce white blood cell count to o30 000, at which point they were able to commence therapy. Signed informed consent was obtained for all study participants and registered by the Data Coordinating Center at the City of Hope. Protocol and consent forms were approved by the institutional review boards of the participating centers.
Treatment plan
Oral tipifarnib was administered b.i.d. on days 1-7 and days 15-21 of each 28-day cycle. The planned dosing levels are presented in Table 1 . Patients received a minimum of one treatment cycle, with no pre-defined maximum number of cycles. Patients were permitted to stay on study as long as there were no unacceptable toxicities. Intra-patient dose escalation was permitted (not beyond the highest dose tested) if CR was not reached in the first cycle and there was no significant toxicity. At the higher dose levels, intravenous hydration was frequently given with the morning tipifarnib dose. For subjects with rapidly rising white blood cell counts after week 1 or 3 of any cycle, hydroxyurea was permitted during the intervening week until 24 h before restarting the next dose of tipifarnib. Allopurinol was started 24 h before the first dose of tipifarnib and continued until at least day 22 of the first cycle.
Evaluation of response
Bone marrow aspiration and biopsies were performed as part of the on-study evaluation within 2 weeks before starting therapy. Patients were seen a minimum of once weekly while on study, with peripheral blood counts and chemistry monitored at least once weekly. Bone marrow studies were repeated between days 26-28 of each cycle. Clinical responses were measured according to the International Working Group criteria. 9 
Study design
Patients were enrolled in cohorts of 3, as per the standard 3 þ 3 phase 1 study design. Patients completed study diaries, which were reviewed as part of the toxicity assessment at each clinic visit. Adverse events were graded using the NCI common toxicity criteria (CTCAE) version 3.0. DLTs were defined as any grade 2-4 non-hematological toxicity possibly related to the study drug, except for nausea, vomiting and diarrhea controllable by routine palliation, any electrolyte disturbance corrected with supplementation, or any grade 4 hematological toxicity in the absence of circulating blasts not reversible to grade 3 or less, by 21 days after the end of a cycle. In the presence of residual leukemia seen upon aspiration, neutropenia and thrombocytopenia did not count as DLT. Dose escalation proceeded if none of the three patients in the cohort had a first cycle DLT. If one of the three patients in a cohort experienced a DLT, three more patients were accrued at that dose level. In the event that a second patient experienced a DLT, that is, two or more out of six patients, then patients were accrued to the next lower dose level. The MTD was defined as that at which no more than one patient out of six experienced a DLT during the first cycle of treatment. Intra-patient dose escalation to the highest dose open for accrual was allowed if CR was not reached in the first cycle. If PR or clinical improvement was not reached after six cycles, patients were categorized as treatment failure and removed from the study.
Pharmacokinetic studies
Venous blood samples were collected in heparinized tubes at the following times during the first cycle: before the dose on day 1, and then at 0.5, 1-3, 5, 8 and 12 h post dosing, and immediately before the dose on day 5, and then at 0.5, 1-3, 5, 8 Tipifarnib for high-risk myeloid leukemia MH Kirschbaum et al and 12 h post dosing. Blood was centrifuged for 10 min at 1000 g within 2 h after collection for separation of plasma, and the resulting plasma samples were stored frozen at oÀ20 1C until batch analysis. Plasma concentrations of tipifarnib were determined using a previously described validated LC-MS/MS assay. 10 Individual plasma concentration-time data were analyzed using standard non-compartmental methods, and the following pharmacokinetic parameters of tipifanib were determined for each patient at the respective doses on days 1 and 5: peak plasma concentration (C max ), time to reach the peak plasma concentration (T max ), area under the plasma concentration-time curve from 0 to 12 h post-dosing (AUC 12h ) and the trough plasma concentration (C min ). In addition, the accumulation index was determined by dividing the AUC 12h on day 5 by the AUC 12h determined on day 1.
Results
A total of 44 eligible patients with AML were enrolled in the study. Demographic data are listed in Table 1 . The median age of patients was 61 (range 33-79) years. Two patients were newly diagnosed; the remaining 42 had relapsed or failed previous therapy, including 5 patients with previous autologous transplant and 2 patients with previous allogeneic transplant.
Toxicity
At the 400 mg b.i.d. dose level, a grade 5 hepatorenal failure occurred, potentially related to the study drug. There were no additional DLTs, and no DLTs at 600, 800 or 1000 mg bid. At the 1200 mg b.i.d. dose level, a grade 3 elevation of the creatinine was seen in one patient out of six treated. At the 1400 mg b.i.d. dose level, in an expanded cohort during dose de-escalation one patient experienced a grade 4 hypotension and a rising grade 2 creatinine that were dose limiting, and a second patient had a rising grade 2 creatinine in cycle 1, where treatment was terminated before it reached a grade 3, and was therefore considered dose limiting. At the 1600 mg dose level, grade 3 liver function tests and a rising grade 2 creatinine were dose limiting, and in a second patient a rapidly rising creatinine was seen and the drug stopped before grade 3 was reached. As a result, the 1200 mg b.i.d. dose was established as the MTD and an additional seven patients were treated at the MTD. In the total of 13 patients who were treated at the 1200 mg b.i.d. dose, there were no grade 4 or 5 toxicities. Grade 2 and 3 toxicities are listed in Table 2 : there was one grade 3 creatinine DLT and grade 2 toxicities included hyperglycemia, fatigue, alopecia, hyperkalemia, mouth sores, shortness of breath, dizziness, nausea, vomiting, ataxia, abdominal pain, headache and dehydration. For this reason, at the higher doses, tipifarnib was administered along with daily intravenous hydration in most patients. Assessing potential hematological toxicities is challenging in AML studies due to the underlying disease; however, among the three patients who achieved CR, one patient developed pancytopenia resulting in an episode of febrile neutropenia upon subsequent cycles of drug.
Clinical activity
The number of patients, DLTs and responses for each individual tipifarnib dose are detailed in Table 3 . One patient at the 1000 mg oral b.i.d. dose who had relapsed after autologous stem cell transplant achieved CR after one cycle, and was taken to allogeneic stem cell transplant, and remains in remission for over 5 years. There were two CRs achieved at the 1200 mg b.i.d. dose: One patient with relapsed disease after standard 7-day cytarabine/3-day daunorubicin induction and one cycle of consolidation entered CR and remained on study for 17 months until relapse; a second patient at the 1200 mg dose level, who had relapsed after first remission and was resistant to second induction, achieved a CR that lasted 1 month. Also at the 1200 mg dose level, a third patient dropped from 50 to 7% marrow blasts after 3 cycles. At the 800 mg b.i.d. dose a patient's marrow blasts decreased from 36 to 10% over three cycles, and at the 1400 mg bid dose bone marrow blasts were decreased by 50% or more in two patients.
Pharmacokinetics
First-dose tipifarnib pharmacokinetic data are available for 10 subjects (Table 4 ) and fifth-dose data for a total of 9 subjects (Table 5) . Three subjects received doses of 1400 mg and seven received 1200 mg b.i.d. The median C max after the first dose on day 1 was 3920 and 906 mg/l in subjects receiving 1400 and 1200 mg, respectively. The median C max after the dose on day 5 was 2630 mg/l in subjects receiving 1400 mg and 1210 mg/l at the 1200 mg dose level. The median C min after the first dose was 237 and 166 mg/l in subjects receiving 1400 and 1200 mg, whereas the median C min after day 5 was 476 and 166 mg/l, respectively. The median AUC 12h after the first dose was 13 835 and 4744 h mg/l in subjects receiving 1400 and 1200 mg, whereas the median AUC 12h after the dose on day 5 was 17 148 and 7366 h mg/l. The median AUC 12h for two patients with decreased blasts was 16 295 and 13 221 h mg/l on days 1 and 5, respectively, while for the remaining patients, the median AUC 12h was 7576 and 4325 h mg/l on days 1 and 5, respectively. Similarly, median C max for these two patients was 2442.5 and 2550 mg/l on days 1 and 5, while median C max for the remaining patients was 1290 and 881 mg/l on days 1 and 5, respectively. These differences were not statistically significant. The median accumulation index in subjects receiving doses of 1400 and 1200 mg daily was 1.17 and 1.2, respectively. 
Discussion
Tipifarnib is a methylquinolone analog that competes with the CAAX motif for farnesylation, leading to competitive inhibition of the enzyme FT, which is critical to the function of multiple proteins involved in essential pathways for cell survival. Although initially developed as an agent targeting ras, it appears that tipifarnib may act on multiple pathways, and it is possible that its effects on other farnesylated proteins might be enhanced if higher doses of the drug could be delivered in a safe manner. For this reason we studied escalating doses of tipifarnib in a week-on, week-off schedule, which maintains the molecular activity of the drug while potentially decreasing toxicity. In this phase 1 study, consisting almost entirely of patients with relapsed disease, at the 1000 and 1200 mg BID dosing levels, we saw three CRs, two of which were of long duration, one lasting 17 months and one that enabled the patient to undergo allogeneic stem cell transplant; this patient remains disease free for over 5 years. All these three patients had relapsed disease and cytogenetic abnormalities (trisomy 21, À7, del20). No formal responses were seen among patients treated in the lower dose levels at this schedule.
Tipifarnib pharmacokinetics have been extensively studied at lower doses; [11] [12] [13] however, relatively few data have been reported for doses above 1000 mg. Karp et al. 2 presented data for three subjects receiving 1200 mg and Zujewski et al. 4 reported data for three subjects given doses of 1300 mg. The results presented here are in general agreement with the earlier studies, and, taken together, the data suggest that the pharmacokinetic behavior of tipifarnib is linear up to doses as high as 1400 mg b.i.d. We have also confirmed that relatively modest tipifarnib accumulation occurs between days 1 and 5, even at these higher doses. Although the pharmacokinetic sampling did not include the two patients with complete responses at 1200 mg, there was a 2-3-fold higher median AUC and C max (on both day 1 and day 5) observed in the two patients with decreased blasts assayed when compared with the median of the non-responders. The current data also indicate a significant degree of both inter-and intra-patient variability in tipifarnib pharmacokinetics. The potential sources of such variability, as well as its clinical impact, need to be further elucidated.
Although the expansion group is too small (seven patients) to cause concern, it is interesting that no complete responses were seen in this group. However, these were the last patients accrued to the study, raising the theoretical possibility that resistance to tipifarnib could be correlated with previous exposure to hypomethylating agents, which had recently entered standard clinical use. This hypothesis should be examined in a larger study in light of known resistance mechanisms to 5-aza-2 0 -deoxycytidine 14 and tipifarnib. 15 Tipifarnib is an agent with clear activity in leukemia; however, it is increasingly clear that this activity is limited to diseases with certain characteristics, best typified thus far by the Table 3 Outcomes for each tipifarnib dose correlation with the RASGRP1/APTX ratio as determined by gene signature analysis. Our study suggests that clinical studies designed to study the role of tipifarnib in these populations should consider higher doses on a week-on, week-off schedule.
